IBC Pharmaceuticals, Inc.

IBC Pharmaceuticals, Inc.

IBC Pharmaceutical, Inc., (IBC) is a biopharmaceutical company focused on the development and commercialization of antibody-based, diagnostic and therapeutic products for the detection and treatment of cancers and other serious diseases. Founded as a joint venture of Immunomedics, Inc. and Beckman Coulter in 1999, IBC became a majority-owned subsidiary of Immunomedics when Beckman Coulter’s interest in the joint venture was acquired by Immunomedics in 2002.

IBC’s goal is to develop and commercialize a portfolio of proprietary pretargeting agents for the detection and treatment of various cancers and other serious diseases. These products will be based on IBC’s patented technology platform referred to as the “Affinity Enhancement System,” or AES. In clinical trials to date, AES has demonstrated significantly improved targeted delivery of imaging agents and therapeutics to specific tumors. The AES therapy approach makes use of two different reagents: the first is a tumor-targeting bispecific antibody (bsMAb) and the second is a divalent hapten carrying an imaging or therapeutic agent, to which the pre-targeted bsMAb binds with high affinity. The bsMAb has the ability to recognize both the target tumor cell and the divalent hapten carrying the imaging or therapeutic agent. One key attribute of AES is that the divalent hapten itself can also bind to two bsMAbs and is thus capable of cross-linking the bsMAbs already bound to the target cell, resulting in a very stable complex of bsMAb-hapten at the cell surface. The free hapten that is not bound to the bsMAb is quickly eliminated from the body via the urine (Figure 1). By replacing the molecule conjugated to the hapten from a diagnostic tracer to a cytotoxic agent, the same antibody used for imaging can be applied to therapy. This use of the imaging component of AES-based pretargeting together with its therapeutic component permits IBC to select patient populations that over-express a particular antigen, and then develop therapy targeted to that antigen. The advantage of this approach over the current therapy is that these patients will have a high probability of benefiting from the therapy. The ultimate goal of IBC is to offer cancer patients a more personalized targeted treatment.

Graphic for IBC page

Selected Literature

  • van Rij CM, Lütje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM, McBride WJ, Rossi EA, Oyen WJ, Boerman OC. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging. 40(9): 1377-83, Sep 2013.
  • Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CM, Franssen GM, McBride WJ, Chang CH, Rossi EA, van der Graaf WT, Oyen WJ. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 109(4): 934–942, Aug 20, 2013.
  • Rijpkema M, Sharkey R, Bos D, McBride W, Oyen W, Goldenbeg DM, Boerman O. SPECT/fluorescence dual-modality imaging of carcinoembryonic antigen-expressing tumors: a pretargeting study. Annual Congress of the European Association of Nuclear Medicine (EANM), Oct 20, 2013 (Abstr. #OP261). Eur J Nucl Med Mol Imaging (2013) 40 (Suppl 2): S89-S567.
  • Sharkey RM, Chang CH, Rossi EA, McBride WJ, Goldenberg DM. Pretargeting: taking an alternate route for localizing radionuclides. Tumor Biol. 33(3):591-600, 2012.
  • Schoffelen R, van der Graaf WTA, Sharkey RM, Franssen GM, McBride WJ, Chang CH, Bos DL, Goldenberg DM, Oyen WJ, Boerman OC. Qantitative Immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer. J Nucl Med. 53(12):1926-32, 2012.
  • Schoffelen R, van der Graaf WTA, Sharkey RM, Franssen GM, McBride WJ, Chang CH, Laverman P, Goldenberg DM, Oyen WJ, Boerman OC. Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. Eur J Nucl Med Mol Imag Res. 2(5):1-9, 2012.
  • Salaun PY, Campion L, Bournaud C, Faivre-Chauvet A, Vuillez JP, Taieb D, Ansquer C, Rousseau C, Borson-Chazot F, Bardet S, Oudoux A, Cariou B, Mirallie E, Chang CH, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: Biomarker response and survival improvement. J Nucl Med. 53(8):1185-92, 2012.